Truist analyst David MacDonald raised the firm’s price target on Pediatrix Medical (MD) to $24 from $17 and keeps a Hold rating on the shares. The firm is updating its model to reflect the company’s Q3 earnings beat and guidance raise, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MD:
- Pediatrix Medical price target raised to $23 from $16.50 at UBS
- Pediatrix Medical Group: Strong Financial Performance and Strategic Improvements Justify Buy Rating
- Pediatrix Medical reports Q3 adjusted EPS 67c, consensus 47c
- Pediatrix Medical raises FY25 adjusted EBITDA view to $270M-$290M
- MD Earnings this Week: How Will it Perform?